[In vivo antitumor effects of polyethylene glycol--modified recombinant human interleukin-2 on mouse uterine cervical carcinoma].
Polyethylene glycol (PEG-8000) -modified recombinant human interleukin-2 (PEG-rIL-2) is a cytokine with prolonged circulatory half-life. In this paper, the antitumor effects of PEG-rIL-2 against mouse uterine cervical carcinoma (U14) transplanted intraperitoneally or subcutaneously is reported. PEG-rIL-2 at different doses was administered intratumorally. The results showed that PEG-rIL-2 (4,500 IU, i.p., QD x 5) prolonged survival time of mice bearing ascites tumor as compared to rIL-2 (P < 0.01), but PEG-rIL-2 at lower doses was without therapeutic effect. In addition, compared to rIL-2, PEG-rIL-2 at different doses (1,500-13,500 IU, QD x 5) caused significant dose-dependent growth inhibition of solid tumor (P < 0.01) when the treatment started on lay 4 after subcutaneous inoculation of tumor.